The Relative Strength (RS) Rating for Incyte entered a new percentile Monday, with an increase from 77 to 82.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Incyte is building a consolidation with an 83.95 buy point. See if it can clear the breakout price in volume at least 40% above average.
Earnings growth increased in the company's most recent report from -3% to 35%, but the top line fell from 24% to 16%.
The company earns the No. 25 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech, United Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
